OT's own Martin Shkreli arrested


Well-Known Member
Mar 14, 2000
Silicon Valley, CA USA

How drugmakers set their prices


How Pfizer set the cost of its new drug at $9,850 a month

Process of setting the price for breast-cancer treatment shows arcane art behind rising U.S. drug prices

By Jonathan D. Rockoff / 21 hours ago

Days before Pfizer Inc. was to set the price for a new breast-cancer drug called Ibrance, it got a surprise: A competitor raised the monthly cost of a rival treatment by nearly a thousand dollars.

Three years of market research—a stretch that started almost as soon as the new treatment showed promise in the laboratory—was suddenly in doubt. After carefully calibrating the price to be close to rivals and to keep doctors and insurers happy, Pfizer was left wondering if its list price of $9,850 a month for the pills was too low.

“What do you think if we take that up?” asked Albert Bourla, Pfizer’s executive overseeing cancer drugs, speaking to his colleagues at the final price-setting meeting last January.

It was a tricky issue. Drug companies have been reaching for new heights of pricing. They routinely raise the cost of older medicines and then peg new ones to these levels.

Yet Pfizer knew setting a price too high for Ibrance might backfire. It could antagonize doctors and prompt health insurers to make prescribing the pills a cumbersome process with extra paperwork that doctors dislike.

A look at Pfizer’s long journey to set Ibrance’s price—a process normally hidden from view—illuminates the arcane art behind rising U.S. drug prices that are arousing criticism from doctors, employers, members of Congress and the public. A Senate committee is holding a drug-price hearing on Wednesday, focusing on sudden large increases imposed by companies that purchased the rights to drugs developed by others.

The average cost of a branded cancer drug in the U.S. is around $10,000 a month, double the level a decade ago, according to data firm IMS Health. Cancer doctors say high costs are unavoidable because all of the options are pricey.

“I think that says something about where we all are in terms of drug costs: We’ve gotten used to something that is pretty outrageous,” says Eric Winer, who heads the women’s cancers division at Dana-Farber Cancer Institute in Boston.

Pfizer’s multistep pricing process shows drugmakers don’t just pick a lofty figure out of the air. At the same time, its process yielded a price that bore little relation to the drug industry’s oft-cited justification for its prices, the cost of research and development.

Instead, the price that emerged was largely based on a complex analysis of the need for a new drug with this one’s particular set of benefits and risks, potential competing drugs, the sentiments of cancer doctors and a shrewd assessment of how health plans were likely to treat the product.

In the end, “we went to the right point where patients get the maximum access, payers will be OK and Pfizer will get the [returns] for a breakthrough product,” Dr. Bourla said..................




On the rights of your wealth, I disagree
OT Supporter
Aug 28, 2002
Liberal Enclave of Darien, CT
courtroom sketch :rofl:



OT Supporter
Feb 20, 2005
My point is that there are tons of assholes in healthcare, but someone this guy is singled out and the others are ignored or patted on the back. Why?

who's patting the others on the back?

martin's an attention seeker so it's not surprising that he's getting attention


America: The most RACIST nation in world history!
Jul 16, 2001
cmon let me come over and lick ur clit. I know you have nothing better to do. no reciprocation. lol.

Users who are viewing this thread

About Us

  • Please do not post anything that violates any Local, State, Federal or International Laws. Your privacy is protected. You have the right to be forgotten. Site funded by advertising, link monetization and member support.
OT v15.8.1 Copyright © 2000-2022 Offtopic.com
Served by fu.offtopic.com

Online statistics

Members online
Guests online
Total visitors

Forum statistics

Latest member